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Abstract: Homocysteine is a sulfur-containing aminoacid produced during metabolism of 
methionine. Since 1969 the relationship between altered homocysteine metabolism and both 
coronary and peripheral atherotrombosis is known; in recent years experimental evidences 
have shown that elevated plasma levels of homocysteine are associated with an increased risk 
of atherosclerosis and cardiovascular ischemic events. Several mechanisms by which elevated 
homocysteine impairs vascular function have been proposed, including impairment of endothelial 
function, production of reactive oxygen species (ROS) and consequent oxidation of low-density 
lipids. Endothelial function is altered in subjects with hyperhomocysteinemia, and endothelial 
dysfunction is correlated with plasma levels of homocysteine. Folic acid and B vitamins, required 
for remethylation of homocysteine to methionine, are the most important dietary determinants 
of homocysteine and daily supplementation typically lowers plasma homocysteine levels; it is 
still unclear whether the decreased plasma levels of homocysteine through diet or drugs may 
be paralleled by a reduction in cardiovascular risk.
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Introduction
The homocysteine “hypothesis of arteriosclerosis” was ﬁ  rst proposed by McCully 
(1969), who observed premature atherothrombosis of the peripheral, coronary, and 
cerebral vasculature in children with homocystinuria, an inborn error in methionine 
metabolism. In 1976, Wilcken and Wilcken provided the ﬁ  rst evidence of a relationship 
between abnormal homocysteine metabolism and coronary artery disease (CAD) in the 
general population (Wilcken and Wilcken 1976). Since these seminal observations, 
results from a large number of clinical and epidemiologic investigations have implied 
a role for homocysteine in atherosclerotic cardiovascular disease (CVD) (Welch and 
Loscalzo 1998; The Homocysteine Studies Collaboration 2002; Wald et al 2002, 
2006). The aim of this paper was to survey the state of the art regarding homocysteine, 
cardiovascular risk and its potential reduction by homocysteine lowering; several 
studies available on Medline was selected using “homocysteine”, “CVD risk”, “folate 
and vitamin B therapy” as key words up to 2007. The overall strength of the evidence 
in these publication was evaluated according to a widely used criteria: the ﬁ  rst level 
of evidence included multiple, well-designed, randomized controlled clinical trials; 
the second one included multiple well-designed cohort or case-control studies, or 
well-designed meta-analysis and the third level include smaller or less optimal designed 
studies or descriptive studies.
Homocysteine metabolism
Homocysteine is a sulfur-containing amino acid produced in the metabolism of the 
essential aminoacid methionine. Homocysteine is metabolized through two path-
ways: remethylation and transsulfuration. In remethylation, homocysteine aquires Therapeutics and Clinical Risk Management 2008:4(1) 220
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a methyl group from methyltethrahydrofolate (MTHF) 
to form methionine in a vitamin B12-dependent reaction. 
The formation of the methyl donor MTHF depends on the 
presence of methylentethrahydrofolate, derived from dietary 
folate, and methylentethrahydrofolate reductase (MTHFR). 
A considerable proportion of the methionine formed in this 
pathway is then activated by adenosine triphosphate (ATP) 
to form S-adenosylmethionine (SAM). SAM serves primarly 
as a universal methyl donor to a variety of acceptors includ-
ing nucleic acids, neurotransmitters, phospholipids, and 
hormones. S-adenosylhomocysteine (SAH), the byproduct 
of these methylation reactions, is subsequently hydrolized, 
thus generating homocysteine, which then becomes avaible 
tro start a new cycle of methyl-group transfer. In the trans-
sulfuration pathway, homocysteine condenses with serine to 
form cystathionine in an irreversible reaction catalyzed by 
the pyridoxal phosphate-containing enzyme, cystathionine 
β-synthase (CBS). Cystathionine is hydrolyzed to form 
cysteine, the excess of which is excreted in the urine. Thus, 
this transsulfuration pathway effectively catabolyzes excess 
homocysteine which is not required for methyltransfer. 
Because of the existance of a cellular homocysteine export 
mechanism, plasma normally contains a small amount of 
homocysteine averaging 10 µmol/L. This export mechanism, 
together with transsulfuration pathway, helps maintain low 
intracellular concentration of this potentially cytotoxic sulfur 
amino acid. The occurance of hyperhomocysteinemia indi-
cates that homocysteine metabolism has in some way been 
disrupted and that the export mechanism is disposing into the 
blood excess homocysteine. This export mechanism limits 
intracellular toxicity, but leaves vascular tissue exposed to 
the possible deleterious effects of excess homocysteine.
Hyper-homocysteinemia 
determinants
Genetic causes
Congenital homocystinuria associated with severe hyper-
homocysteinemia is caused by homozygous defects in the 
gene encoding for CBS. This condition is unquestionaby 
associated with precocious atherosclerosis and extensive 
arterial thrombosis. In these patients, the main cause of 
mortality and morbidity is thromboembolism, followed by 
cerebrovascular accident, peripheral arterial thrombosis, and 
myocardial infarction. Rarely, homocystinuria is caused by 
low methionine sintase activity, or severe defects of MTHFR 
(Rosenblatt and Cooper 1990) (Table 1).
However, in 1988 has been reported that two unrelated 
patients with moderate hyperhomocysteinemia and low folate 
levels had a variant of MTHFR that was distinguished from 
the normal enzyme by its lower speciﬁ  c activity (50%) and 
its thermolability (Kang et al 1988). In subsequent studies, 
the same author showed that MTHFR thermolability was an 
inherited recessive trait (Kang et al 1991). After the MTHFR
gene was cloned (Goyette et al 1994), the cause of the 
thermolability was shown to be a commom polymorphism, 
677 C   T, that results in the substitution of an alanine with 
a valine in the catalytic domain of the enzyme. The gene 
frequency for 677 T   C varies among ethnic groups with 
the T allele having a frequency of around 30% in Europeans 
and Japanese but only a frequency of around 11% in Africans 
Americans (Schneider et al 1998). A second polymorphism, 
1298 A   C, leads to the change of a glutammate to an ala-
nine in the C-terminal regulatory domain of MTHFR and it is 
associated with an approximately 35% decrease in MTHFR 
activity, but not with thermolabiblity (Weisberg et al 1998).
Other causes
Mild (15–20 µmol/L) or moderate (20–50 µmol/L) degrees 
of hyperhomocysteinemia are generally the result of acquired 
disorders (Table 1). The most frequent causes are deﬁ  ciencies 
of vitamins that are required as cofactors or substrate for 
homocysteine metabolism: actually, serum homocysteine 
levels show an inverse correlation with serum vitamin B12, 
B6 and folate. Consequently, plasma homocysteine can be 
increased by various drugs and condition that interfere with 
folate, vitamin B12 and vitamin B6 metabolism.
Table 1 Major determinants of serum/plasma homocysteine 
concentration
Homocysteinemia determinants
Genetic factors
 CBS  deﬁ  ciency (homocystinuria)
  Methionine synthase deﬁ  ciency (homocystinuria)
  Methionine synthase reductase deﬁ  ciency (homocystinuria)
  MTHFR C677T (TT genotype)
Physiological determinants
 Increasing  age
 Male  sex
 Pregnancy
 Postmenopausal  state
  Increasing muscular mass
Lifestyle determinants
  Folate, vitamin B12, B6, B2 intake
 Smoking
 Coffee
 Exercise
Clinical conditions
  Folate, vitamin B12, B6 deﬁ  ciency
 Renal  failure
  Early and late stage of diabetesTherapeutics and Clinical Risk Management 2008:4(1) 221
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Renal impairment commonly causes hyperhomocystein-
emia, probably not because of impaired urinary excretion, 
wich is a minor route for direct homocysteine clearance, but 
because of impaired metabolism of homocysteine by the 
kidney, the major route by which homocysteine is cleared 
from plasma (Bostom and Lathrop 1997).
Homocysteinemia assessment
Homocysteine is present in plasma in four forms: about 1% 
circulate as the free thiol; 70%–80% is disulﬁ  de-bound to 
plasma proteins, chieﬂ  y albumin; the remaining 20%–30% 
combines with itself to form the homocysteine dimer or 
with other thiols, including cysteine, with which it forms the 
homocysteine-cysteine mixed disulﬁ  de (Ueland 1995). The 
term “total plasma (or serum) homocysteine” (tHcy) refers 
to the combined pool of all four forms of homocysteine.
In all available assays, plasma or serum is initially treated 
with a reducing agent that converts all Hcy species into the 
reduced form HcyH, which is measured either directly or 
after derivatization. Brieﬂ  y, tHcy can be determinated in 
serum o plasma by chromatographic methods or by enzyme 
and immunoassays. The chromatographic assays include 
wide analytical range, simultaneous determination of other 
compounds (other sulfur aminoacids), and sometimes lower 
cost than commercial reagent-based assays, but they usually 
require skilled staff, are labour-intensive, and throughput 
may be low. On the other hand, widley used enzyme and 
immunoassays are usually simple to perform, satisfact 
analytic criteria, and give comparable results, so they are 
now suitable for routine laboratories (Refsum et al 2004).
The determination of tHcy can be done in a fasting state 
or after methionine load; post-load tHcy is probably more 
sensitive than the fasting tHcy to disturbances in the transsul-
furation pathway such as those caused by CBS or vitamin B6 
deﬁ  cency (Refsum et al 1997).
Homocysteine and cardiovascular 
disease
Pathophysiologic mechanisms
The mechanisms by which elevated homocysteine impairs 
vascular function are not completely understood. Laboratory 
investigations have revealed several potential mechanisms, 
including impairment of endothelial function (Woo et al 1997), 
production of reactive oxygen species (ROS) and consequent 
oxidation of low-density lipids (Pfanzagl et al 2003; Hayden 
and Tyagi 2004), increased monocyte adhesion to the ves-
sel wall (Welch and Loscalzo 1998), increased lipid uptake 
and retention (Welch and Loscalzo 1998), activation of the 
inﬂ  ammatory pathway (Hofmann et al 2001), stimulatory 
effects on smooth-muscle proliferation (Welch and Loscalzo 
1998), thrombotic tendency mediated by activation of coagula-
tion factors (Undas et al 2001), hypoﬁ  brinolysis (Lauricella 
et al 2006), and platelet dysfunction (Ungvari et al 2000). The 
atherogenic and thrombogenic potentials of homocysteine have 
been implicated in promoting endothelial dysfunction induced 
by acute hyperhomocysteinemia after methionine loading in 
human subjects (Bellamy et al 1998), facilitating the progres-
sion of atherosclerotic plaque in apolipoprotein E-deﬁ  cient 
mice (Hofmann et al 2001), promotion of prothrombotic 
state (Welch and Loscalzo 1998), and exacerbation of inti-
mal hyperplasia and restenosis after balloon injury of arteries 
(Morita et al 2001; Cook et al 2002). These ﬁ  ndings provide 
a coherent and biologically plausible basis for a direct role for 
homocysteine in promoting atherothrombosis.
Hyperhomocysteinemia
and cardiovascular risk
The results of early cross-sectional and case-control studies 
strongly support that tHcy measured in serum or plasma is 
a strong predictor of cardiovascular disease risk (Ueland 
and Refsum 1989; Boushey et al 1995; Refsum et al 1998; 
Hankey and Eikelboom 1999). Since 1992, however, the 
results of several large, well-conducted prospective studies in 
which blood samples were collected before the cardiovascular 
event showed weaker relations and gave a less consistent 
picture (Christen et al 2000; Ueland et al 2000). Some 
prospective studies showed a strong association between 
tHcy and cardiovascular disease (Arnesen et al 1995; Perry 
et al 1995; Wald et al 1998; Bots et al 1999; Ridker et al 
1999), some found weaker association (Stampfer et al 1992; 
Giles et al 1998; Stehouwer et al 1998; Ubbink et al 1998), 
and others, including the Multiple Risk Factor Intervention 
Trial and the Atherosclerosis Risk in Communities Study, 
failed to ﬁ  nd any signiﬁ  cant associations (Evans et al 1997; 
Folsom et al 1998). The reasons for these conﬂ  icting results 
have not been fully explored, but may be related to differ-
ences in diet, lifestyle, and other cardiovascular risk factors, 
and to characteristics including lenght of follow-up and 
blood sample handling and storage. Notably, prospective 
studies of patient populations known to be at high risk of 
cardiovascular events consistently report strong positive 
association between tHcy and cardiovascular morbidity or 
mortality (Nygård et al 1997; Moustapha et al 1998; Kark 
et al 1999; Stehouwer et al 1999; Taylor et al 1999). In 
follow up studies of the Framingham cohort tHcy was shown 
to have strong and signiﬁ  cant associations of similar strengthTherapeutics and Clinical Risk Management 2008:4(1) 222
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with both all-cause and cardiovascular disease (Bostom 
et al 1999). The results of several investigations have been 
compiled in a large meta-analysis conducted by The 
Homocysteine Studies Collaboration (The Homocysteine 
Studies Collaboration 2002); the aim of this collaborative 
meta-analysis was to combine individual participant data 
from 12 prospective and 18 retrospective studies from 1966 
to 1999 to produce reliable estimates of the associations of 
tHcy with ischemic heart disease (IHD) and stroke. A total 
of 5,073 coronary artery disease events and 1,113 stroke 
events were observed among 16,786 healthy individuals. 
The results showed that among prospective studies of indi-
viduals with no history of cardiovascular disease, and after 
appropriate adjustment for known cardiovascular risk fac-
tors and correction for regression diluition bias, a 25% lower 
usual homocysteine level was associated with about an 11% 
lower IHD and about a 19% lower stroke risk. Moreover, 
the risk of IHD and stroke associated with homocysteine 
levels was signiﬁ  cantly weaker in the prospective studies 
than the retrospective studies; this result may reﬂ  ect bias 
in retrospective studies caused by difﬁ  culties of selecting 
appropriate controls, the effects of changes in treatment, 
renal function, or other factors after the onset of disease 
that produce increases in homocysteine concentrations 
among the cases.
Impact of homocysteinemia 
lowering on cardiovascular disease
Increases in homocysteinemia are common and can easily 
be corrected with safe and inexpensive therapy. Folic acid 
and B vitamins, required for remethylation of homocysteine 
to methionine, are the most important dietary determinants 
of homocysteine. Daily supplementation with 0.5–5.0 mg 
of folic acid typically lowers plasma homocysteine levels 
by about 25%; vitamin B12 supplementation of at least 0.4 
mg daily further lowers levels by about 7%, and vitamin 
B6 supplements may be particularly important in lowering 
homocysteine after methionine loading (Homocysteine 
Lowering Trialists’ Collaboration 2002). These observations 
have formed the basis of large-scale intervention trials that 
are seeking to determine whether lowering homocysteine 
concentrations through B vitamin supplementation can 
decrease cardiovascular risk in healthy subjects or improve 
survival in patients with coronary heart disease. The effects 
of prolonged administration of folate combined with vitamins 
B6 and B12 on cardiovascular risk have been analyzed in 
a large, prospective, randomized clinical trial (The Heart 
Outcomes Prevention Evaluation (HOPE) 2 Investigators 
2006). In this study, 2758 subjects were randomly assigned 
to active treatment with folic acid, vitamin B12 and B6 versus 
2764 assigned to placebo; the primary study outcome was the 
composite of death from cardiovascular causes, myocardial 
infarction and stroke. Results demonstrate that daily adminis-
tration lowered homocysteine levels signiﬁ  cantly but did not 
reduce the incidence of the primary outcome during a mean 
follow-up period of ﬁ  ve years. These results are consistent 
with those of the Norwegian Vitamin (NORVIT) trial (Bonaa 
et al 2006); this trial evaluated 3749 patients with recent 
myocardial infarction and found no signiﬁ  cant beneﬁ  cial 
effects of combined treatment with folate and vitamin B12, 
with or without vitamin B6, in spite of adequate homocysteine 
lowering. Simillary, there was no treatment beneﬁ  t in the 
Vitamin Intervention for Stroke Prevention (VISP) study 
and in a smaller trial conducted in 593 patients with stable 
coronary heart disease in the Netherlands (Liem et al 2003; 
Toole et al 2004). A plausible explanation for the discordance 
between the epidemiology of homocysteine and the results 
of the clinical trials may be related to inherent limitations of 
observational studies.
Conclusions
Although several studies focusing on the role of homocysteine 
in cardiovascular disease have been conducted, there isn’t 
fully agreement on this topic. Homocysteine levels are related 
to renal dysfunction, smoking, elevated blood pressure, and 
other cardiovascular risk factors; moreover, homocysteine 
levels are higher in people with atherosclerosis than in those 
without. Therefore, homocysteine could be a marker, but not 
a cause, of vascular disease, and the epidemiologic data could 
be the result of residual confounding that cannot be fully 
adjusted for, of reverse causality, or both. Routine screening 
for elevated homocysteinemia is not yet recommended. 
However, screening may be advisable for individuals who 
manifest atherotrombotic disease that is out of proportion to 
their traditional risk factors or who have a family history of 
premature atherosclerotic disease.
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